类有机物
乳腺癌
癌症研究
效应器
免疫疗法
细胞毒性
肿瘤浸润淋巴细胞
转录组
癌症免疫疗法
医学
细胞
信号转导
细胞凋亡
渗透(HVAC)
内生
细胞溶解
生物
串扰
癌症
单克隆抗体
人体乳房
乳腺肿瘤
化学
癌细胞
肿瘤微环境
生物标志物
作者
Xiaolong Zhou,Yu Zhu,George Michael Nicolas,Fulin Zhou,Davit Khutsishvili,Wanlong Wang,Zhuoyao Song,Wenxin Xu,Yu Ye,Yu Zhang,Zitian Wang,Peter Edward Lobie,Shaohua Ma
出处
期刊:Cell Reports
[Cell Press]
日期:2026-02-01
卷期号:45 (2): 116987-116987
被引量:5
标识
DOI:10.1016/j.celrep.2026.116987
摘要
Triple-negative breast cancer (TNBC) remains resistant to immunotherapy because of its profoundly immunosuppressive tumor microenvironment. Here, we establish a droplet-engineered organoid (DEO) platform that preserves endogenous TILs and supports rapid, immunocompetent drug evaluation. Optimizing ROCK pathway modulation reveals that early withdrawal of Y-27632 maintains TIL viability, whereas ROCK activation by pentanoic acid (PA) substantially enhances CD8 + T cell infiltration and cytotoxicity within DEOs. In 4T1 tumor-bearing mice, PA monotherapy or alternating PA/Y-27632 treatment significantly reduces tumor volume without detectable systemic toxicity. To validate translational relevance, we applied PA to patient-derived organoids, which exhibited increased T cell activation and abundance, along with a higher proportion of apoptotic cells within the organoid. Integrated transcriptomic and protein analyses reveal that PA induces a cytolytic program coupled to ROCK-dependent effector pathways. Clinical dataset analyses further associate ROCK activation signatures with improved overall survival in basal-like immune-suppressed (BLIS) subtype TNBC. Collectively, our findings highlight that alternating ROCK pathway modulation, in particular ROCK activation, is a promising strategy to convert TNBC into an immune-responsive state.
科研通智能强力驱动
Strongly Powered by AbleSci AI